Drug discovery relies heavily on known chemical libraries, but the vast majority of microbial chemistry—shaped by billions of years of evolution—remains inaccessible, limiting the pool of novel bioactive compounds for new therapeutics.

Generare provides an industrial-scale platform that extracts, purifies, identifies, and annotates previously unread microbial molecules directly from their natural biological contexts. By unearthing this hidden 97% of microbial chemistry, the company creates unique, high‑quality molecular data that have never been seen by AI models or researchers. Each newly discovered compound is characterized for its natural function, enabling rapid translation into first‑in‑class drug candidates across therapeutic areas such as antibiotics and oncology. The continuously expanding proprietary dataset improves predictive selection, creating a feedback loop that accelerates the discovery of novel, evolution‑derived medicines.

Large‑scale extraction and purification workflow that isolates native microbial metabolites at industrial throughput

Comprehensive analytical pipeline for structural identification and functional annotation of unknown molecules

Proprietary data generation that adds unique, never‑before‑trained data points to AI‑driven drug discovery models

Integrated platform that links molecule discovery to downstream drug development, supporting rapid lead optimization

Continuous learning loop where each new compound enriches the dataset, enhancing future selection accuracy

Generare serves pharmaceutical companies and biotech firms seeking novel, biologically active scaffolds for antibiotic, oncology, and other therapeutic pipelines.